An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data

• Автори: Alexander D. James (Автор), Hilmar Schiller (Автор), Cyrille Marvalin (Автор), Yi Jin (Автор), Hubert Borell (Автор), Ad F. Roffel (Автор), Ulrike Glaenzel (Автор), Yan Ji (Автор), Gian Camenisch (Автор)
• Формат: Книга
• Опубліковано: Wiley, 2020-06-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Abstract Ribociclib (LEE011, Kisqali ®) is a highly selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6 (CDK4/6), which has been approved for the treatment of advanced or metastatic breast cancer. A human ADME study was conducted in healthy male volunteers following a single oral...